Switching patients who are doing well on their current Gaucher disease treatment to a different medication comes with risks, and it may be “inappropriate” for health insurers to require a change to cut costs, according to a study from Quebec. Gaucher disease patients who switched their enzyme…
Bone manifestations — including pain, structural changes, and reduced bone density — are common among people with Gaucher disease in Tunisia, according to a study. Although bone disease affected nearly two-thirds of patients, it was rarely the main reason treatment was started. Only slightly more than half of those…
Available disease-modifying therapies (DMTs) for Gaucher disease can decrease the levels of lyso-Gb1, a biomarker of disease burden, but levels remain significantly above the normal range in treated patients, a study found. “We speculate that the persistently increased lyso-Gb1 levels may have been driven by underlying mechanisms, such as…
